Integrated BioPharma, Inc. (INBP) Fair Value 2026

INBP · Packaged Foods ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.4 /10

32 fundamental signals · 8 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, Integrated BioPharma, Inc. (INBP) trades at $0.18, versus a $0.79 median fair value across its 8 active models — 337.6% above the current price. QOC: 7.4/10. Value Trap Risk: 26/100 (LOW). 8/13 models active. Within that set, the Bayesian DCF component alone returns $0.86.

Key Facts

Ticker
INBP
Price
$0.18
Quality Score
7.4/10
Value Trap Risk
26/100
Models Active
8/13
Last Updated
Strength: Bayesian DCF suggests +376.3% upside with 66% confidence
Risk: Limited model coverage (8/13) may reduce confidence

Is Integrated BioPharma, Inc. (INBP) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Integrated BioPharma, Inc. (INBP) appears undervalued as of : the median of 8 independent fair value estimates is $0.79, 337.6% above the current price of $0.18. Estimates range from $0.31 to $1.02. INBP scores 7.4/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. INBP’s +337.6% gap is wider than that market norm, and the Packaged Foods sector median is -16.6%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Integrated BioPharma, Inc. Stock in 2026? →

What Fair Value Does Each Model Give INBP?

8 Intrinsic Value Models vs. Current Price ($0.18)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.86 +376.3%
Intrinsic · High Conviction
 $0.63 +250.1%
Ensemble · Medium Conviction
 $0.79 +340.8%
Intrinsic · High Conviction
 $0.57 +219.3%
Unlock the Full Matrix

Access 4 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is INBP's Fair Value Range?

Spread across 8 independent models · $0.31 to $1.02

CirclFi's 8 active models place Integrated BioPharma, Inc. (INBP) between $0.31 and $1.02 per share, a spread of 90% of the median. The median of that range — $0.79 — is the fair value CirclFi publishes for INBP, against a current price of $0.18.

Low · Regime CrossHigh · FTNN
$0.31median $0.79$1.02
Where the range comes from
Most bearish modelRegime Cross-Sectional$0.31
Most bullish modelFTNN Topology$1.02
Model agreement8 bullish · 0 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on INBP, not a CirclFi price target. How each model works →

What Is Integrated BioPharma, Inc. (INBP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Integrated BioPharma, Inc.. Trading at $0.18 against an estimated intrinsic value of $0.79, 8 of 8 active models flag meaningful upside of +337.6% at the median. The most optimistic model, FTNN, places fair value at $1.02 (+464.6%), while Regime Cross — the most conservative — estimates $0.31 (+72.8%). This +391.9% gap reflects genuine analytical uncertainty about Integrated BioPharma, Inc.'s intrinsic worth. Among models with highest confidence, EPV lean bullish — adding weight to the bullish side of the thesis.

What Do the Models Say About INBP?

8 of 13 models are currently active for INBP. All 8 active models suggest the stock trades below fair value. Taken together, their median fair value for INBP is $0.79 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.86 on its own, implying +376.3% upside from the current price. See which stocks rank higher →

How Does INBP Rank in Packaged Foods?

Among 81 Packaged Foods stocks, INBP ranks #25 by Quality of Company score. CirclFi's QOC score of 7.4/10 evaluates 32 fundamental signals. A score of 7.4 indicates above-average quality.

See all Most Undervalued Packaged Foods Stocks →

As a consumer sector, Integrated BioPharma, Inc. operates in a sector where gross margin expansion is a critical driver of valuation. Investors evaluating INBP should weigh these sector-specific dynamics alongside our model-derived fair values.

Is INBP a Value Trap?

CirclFi's Value Trap algorithm assigns INBP a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Integrated BioPharma, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Integrated BioPharma, Inc.'s fundamental quality profile registers 7.4/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +391.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every INBP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across INBP's 8 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Integrated BioPharma, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Packaged Foods Stocks Should You Also Analyze?

11 related Packaged Foods stocks with 13-model coverage

USNAUSANA Health Sciences, Inc.QOC 7.5HLFHerbalife Ltd.QOC 7.3MICCThe Magnum Ice Cream Company N.V.QOC 7.5CPBThe Campbell's CompanyQOC 7.3JBSJBS N.V.QOC 7.5NOMDNomad Foods LimitedQOC 7.2BYNDBeyond Meat, Inc.QOC 5.7ATPCAgape ATP CorporationQOC 4.8MAMAMama's Creations, Inc.QOC 8.8PPCPilgrim's Pride CorporationQOC 9.0JJSFJ&J Snack Foods Corp.QOC 8.9

Read investment analysis: USNA · HLF · MICC · CPB · JBS · NOMD · BYND · ATPC · MAMA · PPC · JJSF

Which Other Stocks Have a Similar Quality Score to INBP?

7 companies across all industries closest to INBP’s Quality of Company score of 7.4/10.

KOPKoppers Holdings Inc.QOC 7.4CACCamden National CorporationQOC 7.4JBLUJetBlue Airways CorporationQOC 7.4LXPLXP Industrial TrustQOC 7.4ATKRAtkore Inc.QOC 7.4CVSCVS Health CorporationQOC 7.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KOP · CAC · JBLU · LXP · ATKR · CVS · NVDA

Where Does INBP Sit in CirclFi's Packaged Foods Rankings?

INBP is ranked against every other Packaged Foods stock CirclFi covers in each of these screens.

See all Packaged Foods stocks ranked →

What Else Do Investors Ask About Integrated BioPharma, Inc.’s Valuation?

What is Integrated BioPharma, Inc.'s intrinsic value in 2026?

CirclFi puts Integrated BioPharma, Inc. (INBP)'s intrinsic value at $0.79 — the median of 8 independent model estimates as of 2026-08-27, ranging from $0.31 to $1.02. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.86 on its own. The Quality of Company score is 7.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is INBP overvalued or undervalued right now?

At $0.18, 8 of 8 active models suggest INBP may be undervalued, while 0 indicate potential overvaluation. The median of all 8 fair value estimates is $0.79, 337.6% above the current price of $0.18 — a consensus view that INBP is undervalued. The assessment depends on which methodology best fits Integrated BioPharma, Inc.'s business model in Packaged Foods.

What does a Quality of Company score of 7.4 mean for INBP?

Integrated BioPharma, Inc.'s QOC of 7.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on INBP?

CirclFi analyzes INBP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on INBP?

Of the 8 models currently active on INBP, FTNN Topology is the most bullish at $1.02 per share, and Regime Cross-Sectional is the most bearish at $0.31. CirclFi's published fair value for INBP is the median of that range, $0.79, not either extreme. The gap between the two ends equals 90% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is INBP a value trap in 2026?

Integrated BioPharma, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Integrated BioPharma, Inc. (INBP) has a median fair value of $0.79 — 337.6% above the current price of $0.18 — as of 2026-08-27.” Source: circlfi.com/stock/INBP/ · Methodology
Primary sources for this INBP valuation
  • Financial statements: Integrated BioPharma, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001016504) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for INBP as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on INBP.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for INBP Unlock All 8 — $39/mo